Q1 Earnings Forecast for APLT Issued By William Blair

Applied Therapeutics, Inc. (NASDAQ:APLT) – Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Applied Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. William Blair analyst S. Corwin expects that the company will earn ($0.17) per share for the quarter. The consensus estimate for Applied Therapeutics’ current full-year earnings is ($0.65) per share. William Blair also issued estimates for Applied Therapeutics’ Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.19) EPS and Q4 2026 earnings at ($0.17) EPS.

Applied Therapeutics (NASDAQ:APLT) last released its quarterly earnings results on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06). The business had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.61 million.

Separately, Royal Bank of Canada restated a “sector perform” rating and issued a $1.50 target price on shares of Applied Therapeutics in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.10.

Applied Therapeutics Stock Up 22.8%

APLT opened at $0.60 on Friday. The stock has a market cap of $85.36 million, a PE ratio of -0.37 and a beta of 2.00. The business has a 50 day moving average of $0.43 and a 200-day moving average of $1.96. Applied Therapeutics has a 52 week low of $0.30 and a 52 week high of $10.62.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. increased its position in Applied Therapeutics by 2,511.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,420,920 shares of the company’s stock valued at $4,642,000 after buying an additional 5,213,370 shares in the last quarter. Marshall Wace LLP increased its position in Applied Therapeutics by 144.8% during the 4th quarter. Marshall Wace LLP now owns 1,307,381 shares of the company’s stock valued at $1,124,000 after buying an additional 773,377 shares in the last quarter. Private Advisor Group LLC bought a new position in Applied Therapeutics during the 4th quarter valued at approximately $35,000. Propel Bio Management LLC increased its position in Applied Therapeutics by 46.4% during the 4th quarter. Propel Bio Management LLC now owns 9,615,420 shares of the company’s stock valued at $8,233,000 after buying an additional 3,047,562 shares in the last quarter. Finally, Alyeska Investment Group L.P. increased its position in Applied Therapeutics by 175.8% during the 4th quarter. Alyeska Investment Group L.P. now owns 2,707,497 shares of the company’s stock valued at $2,318,000 after buying an additional 1,725,824 shares in the last quarter. Institutional investors own 98.31% of the company’s stock.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.